Maritech fucoidan to undergo new clinical trial to research immuno-modulating properties

Article

Marinova is conducting a new clinical trial, in collaboration with Nutrasource, to further explore the immunomodulatory properties of Maritech fucoidan, a marine polysaccharide found naturally in brown seaweed, in healthy adults.

fucoidan

Photo © iStockphoto.com/nicolas_

Marinova (Tasmania, Australia) is conducting a new clinical trial, in collaboration with Nutrasource, to further explore the immunomodulatory properties of Maritech fucoidan, a marine polysaccharide found naturally in brown seaweed, in healthy adults. 

Previous research on Maritech fucoidan has shown that it may:

  • Boost immune responses to vaccines
  • Activate dendritic cells, natural killer cells and T cells
  • Block the entry of coated viruses to cells
  • Reduce lung damage commonly associated with viral infection
  • Support mucosal immune health
  • Dampen allergic responses
  • Modulate stem cell 

The new study is designed to piggyback on existing evidence that suggests Maritech fucoidan acts as an immune priming agent by increasing cytotoxic T cells and natural killer cells, reducing the levels of inflammatory cytokine interleukin-6, and modulating the key market immunoglobulin.

“High-purity, certified organic fucoidan is already included in a multitude of innovative nutritional supplements targeting immune health,” said Marinova’s CEO and managing director, Paul Garrott, in a press release. “Marinova’s investment in this new clinical trial will deepen our understanding of the unique health benefits of Maritech fucoidan.”

Recent Videos
woman working on laptop computer by window
Related Content
© 2024 MJH Life Sciences

All rights reserved.